BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 11724742)

  • 1. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics.
    Chow KB; Wong YH; Wise H
    Br J Pharmacol; 2001 Dec; 134(7):1375-84. PubMed ID: 11724742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting prostacyclin receptor agonist efficacy in different cell types.
    Kam Y; Chow KB; Wise H
    Cell Signal; 2001 Nov; 13(11):841-7. PubMed ID: 11583920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function.
    Wise H
    Prostaglandins Leukot Essent Fatty Acids; 1996 May; 54(5):351-60. PubMed ID: 8832764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon.
    Rudd JA; Qian Ym; Tsui KK; Jones RL
    Br J Pharmacol; 2000 Feb; 129(4):782-90. PubMed ID: 10683203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.
    Seiler SM; Brassard CL; Federici ME; Romine J; Meanwell NA
    Prostaglandins; 1997 Jan; 53(1):21-35. PubMed ID: 9068064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.
    Jones RL; Qian YM; Wise H; Wong HN; Lam WL; Chan HW; Yim AP; Ho JK
    J Cardiovasc Pharmacol; 1997 Apr; 29(4):525-35. PubMed ID: 9156364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of prostacyclin and prostaglandin E(2) receptor mediated responses in adult rat dorsal root ganglion cells, in vitro.
    Rowlands DK; Kao C; Wise H
    Br J Pharmacol; 2001 May; 133(1):13-22. PubMed ID: 11325789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonists can discriminate between cloned human and mouse prostacyclin receptors.
    Chow KB; Jones RL; Wise H
    Prostaglandins Leukot Essent Fatty Acids; 2004 May; 70(5):423-9. PubMed ID: 15062844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of chimeric prostacyclin/prostaglandin D2 receptors: site-directed mutagenesis reveals the significance of the isoleucine residue at position 323.
    Wise H; Chow KB; Wing KY; Kobayashi T; Tse DL; Cheng CH
    J Recept Signal Transduct Res; 2003 Feb; 23(1):83-97. PubMed ID: 12680591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling.
    Hayes JS; Lawler OA; Walsh MT; Kinsella BT
    J Biol Chem; 1999 Aug; 274(34):23707-18. PubMed ID: 10446129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of chimeric prostacyclin/prostaglandin D(2) receptors.
    Wise H
    Eur J Pharmacol; 1999 Dec; 386(1):89-96. PubMed ID: 10611468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase A-mediated phosphorylation of serine 357 of the mouse prostacyclin receptor regulates its coupling to G(s)-, to G(i)-, and to G(q)-coupled effector signaling.
    Lawler OA; Miggin SM; Kinsella BT
    J Biol Chem; 2001 Sep; 276(36):33596-607. PubMed ID: 11443126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of non-prostanoid prostacyclin mimetics on cyclic AMP production by neuronal SK-N-SH cells.
    Wise H; Chow KB
    Adv Exp Med Biol; 1997; 433():197-200. PubMed ID: 9561134
    [No Abstract]   [Full Text] [Related]  

  • 15. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of interaction between prostaglandin E2 receptor subtypes in regulating adenylyl cyclase activity in cultured rat dorsal root ganglion cells.
    Wise H
    Eur J Pharmacol; 2006 Mar; 535(1-3):69-77. PubMed ID: 16545798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of prostacyclin mimetics distinguishes neuronal from neutrophil IP receptors.
    Wise H; Qian YM; Jones RL
    Eur J Pharmacol; 1995 May; 278(3):265-9. PubMed ID: 7589166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase A-dependent coupling of mouse prostacyclin receptors to Gi is cell-type dependent.
    Chow KB; Jones RL; Wise H
    Eur J Pharmacol; 2003 Aug; 474(1):7-13. PubMed ID: 12909190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
    Whittle BJ; Silverstein AM; Mottola DM; Clapp LH
    Biochem Pharmacol; 2012 Jul; 84(1):68-75. PubMed ID: 22480736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of IP and EP(3) receptors alters cAMP-dependent cell migration.
    Blindt R; Bosserhoff AK; vom Dahl J; Hanrath P; Schrör K; Hohlfeld T; Meyer-Kirchrath J
    Eur J Pharmacol; 2002 May; 444(1-2):31-7. PubMed ID: 12191579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.